The trend of using real-world evidence (RWE) in the healthcare industry continues to grow. But perhaps it has never been more important than it is now during the current pandemic. Precisions Dan Danielson and others discuss the benefits to be gained from using RWE in the search for potential diagnostics, drugs and vaccines for COVID-19.
Multiple factors have contributed to recent reductions in cancer mortality, including declines in smoking rates, treatment advances and better screening. But a key question remains: how much have recent developments in oncology treatments contributed to the decline of cancer mortality in the USA?
The complexities and misaligned incentives within our healthcare system have affected the pace of biosimilar adoption in the US.
The gene therapy market is still in its infancy but poised for significant growth, with an approximate 25% increase in therapies in the pipeline as compared to 2018. However, the launch of a gene therapy is an event with limited case examples to follow and numerous unique considerations.
The value of innovation in 2021: There will be a growing need for innovators to justify the value of their products to multiple stakeholders next year, with an increased focus on a treatment’s societal value, how innovation interacts with digital technologies, and whether new innovations are able to reduce existing health outcome inequalities.
The Director-General of the World Health Organization recently declared that regarding COVID-19, “We’re not just fighting an epidemic; we’re fighting an infodemic.”
By Meena Venkatachalam, MSc , Jason Shafrin, PhD
In 2001 the Institute of Medicine named patient centered care one of six keys to delivering high-quality care. How can pharma companies keep patients center stage while in the midst of a digital transformation? Precision’s Marty Samples discusses the four fundamentals of patient-centered care and how pharma marketers can use digital to execute on them.
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
